<DOC>
	<DOCNO>NCT01056393</DOCNO>
	<brief_summary>This protocol serve extend successful treatment HIV positive patient beyond endpoint provide Phase 2b TaiMed Biologics-sponsored protocol TMB202 ( entitle `` A Phase 2b Randomized , Double-Blinded , 48-Week , Multicenter , Dose-Response Study Ibalizumab Plus Optimized Background Regimen Treatment-Experienced Patients Infected HIV-1 ( Amended 24 Week Study ) '' ) , 24 week . Ibalizumab may administer beyond 24 week protocol supply permit patient continue demonstrate virologic response .</brief_summary>
	<brief_title>Investigator-Sponsored Protocol - Continued Use Ibalizumab</brief_title>
	<detailed_description>Ibalizumab administer HIV-infected patient respond ( define minimum 0.7 log10 decline HIV-1 viral load TMB-202 Baseline ) TMB-202 protocol . In addition investigator-selected Optimized Background Regimen , patient ( ) continue receive TMB-202 randomize dose ibalizumab open-labeled fashion ( 800mg IV every two week 2000mg IV every four week ) per original drug assignment TMB-202 protocol .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Capable understand voluntarily sign ICF Have document HIV1 infection Have successfully complete Protocol TMB202 ( Amendment 2 ) ( Week 16 ) Have least 0.7 log10 decline HIV1 RNA baseline Week 16 beyond TMB202 longer eligible participate TMB202 due TMB202 protocoldefined virologic failure Have withdraw discontinue TMB202 9Amendment 2 ) reason Are able willing comply protocol requirement procedure Are 18 year age old If sexually active , willing use effective method contraception study 30days last administration study drug . Any active AIDSdefining illness per Category C except cutaneous Kaposi 's sarcoma wasting due HIV Any significant disease ( HIV1 infection ) clinically significant finding , include psychiatric behavioral problem , medical history and/or physical examination , investigator 's opinion , would preclude patient participate study Any current alcohol illicit drug use , investigator 's opinion , interfere patient 's ability comply study schedule protocol evaluation Any previous clinically significant allergy hypersensitivity excipient ibalizumab formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV</keyword>
</DOC>